Autopsy report · NCT00429858

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

“Study accrual rate is very slow, it was mandated by NCI to be terminated.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years before it stopped.
• 21 participants enrolled.
• Results were posted on the registry 10 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Andrew Ko

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

S-1; gemcitabine hydrochloride

Participants

21

Sites

2

Countries

United States

Trials that died the same way

• Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
  “Study was terminated due to slow accrual rate.” (80% match in meaning)
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  “Study was terminated due to slow accrual.” (77% match in meaning)
• Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
  “Study terminated due to slow accrual.” (74% match in meaning)
• SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
  “Slow accrual was the reason for study termination.” (71% match in meaning)
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  “Study terminated due to slow/insufficient accrual.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.